Importantly, the inhibition of LIFR with EC359 effectively blocks these oncogenic processes, suggesting that LIFR represents a potential therapeutic target for obesity-driven TNBC. This evidence concerns the gene LIFR and obesity due to melanocortin 4 receptor deficiency.